The aim of this study is to further investigate the anti-cancer activity of EC19 and EC23 on RAR-dependent and independent levels through an in vitro approach, including DNA damage activity and interference with the expression/activity of the efflux enzymes and transporters in the Caco-2 cell model. Here, RARA is linked to cancer.